Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease: A Randomized Controlled Trial

NCT07909915 is registered in ClinicalTrials.gov with Rehman Medical Institute - RMI as lead sponsor.

NCT NCT07909915 Not yet recruiting Phase 4 178 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07909915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, Phase 4, 178 participants (estimated). Lead sponsor Rehman Medical Institute - RMI; Pakistan. Primary measure: Achievement of LDL-C Target Levels. 5 linked papers (newest 2024).

How it compares

34 similar trials: same condition (Hypertriglyceridemia) and phase

Enrollment

This trial
178
Middle half
40 to 176
Median
70
Trials with a value
33

Months from start to completion

This trial
7
Middle half
18 to 40.9
Median
26.5
Trials with a value
34

Sites

This trial
1
Middle half
1 to 1
Median
1
Trials with a value
29
Posted results or a linked paper 59% 20 of 34 similar trials; this trial: yes

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease: A Randomized Controlled Trial
Lead sponsor
Rehman Medical Institute - RMI
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
June 30, 2027
Enrollment
178 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Dyslipidemias, Hypercholesterolemia, Hypertriglyceridemia, Stroke

Registry terms: cardio vascular disease, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, stroke (cva) or tia

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Maximum age
80 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
Pakistan
Lead sponsor
Rehman Medical Institute - RMI

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
treat to target Experimental Dose adjustment of statins
Show registry wording

rosuvastatin 10 mg or atorvastatin 20 mg ( to be adjusted as per response of patinet)

Fixed dose Active comparator no dose adjustment
Show registry wording

fixed dose atorvastatin or rosuvastatin

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Achievement of LDL-C Target Levels. 12 weeks
Show registry wording

The proportion of patients with elevated LDL-C who achieve the treatment goal of LDL-C levels \< 55 mg/dL (high risk) and \< 70 mg/dL (low risk) at 4 and 12 weeks of therapy.

Papers

PubMed papers this trial cites; 5 papers, results papers first, then newest first.

Source: PubMed, NCBI/NLM (public domain).

Lead sponsor's other trials

Rehman Medical Institute - RMI, most recent start first.

Similar trials

Same condition (Hypertriglyceridemia) and phase, most recent start first.